Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06172127 · ClinicalTrials.gov registry record · Phase 2
PHESGO Maintenance After T-DXd Short Induction for HER2+ Unresectable Locally Recurrent or Metastatic Breast Cancer
A Phase 2 study of HER2-positive Breast Cancer, sponsored by MedSIR.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 165
- Enrollment target
- 20
- Study locations
NCT06172127 is a Phase 2 study of HER2-positive Breast Cancer that is actively recruiting participants, run by MedSIR. The registered enrollment target is 165 participants, below the 237-participant average among 54 other HER2-positive Breast Cancer trials with a reported enrollment target (30% lower). The trial reports 20 study locations across 3 states.
The verdict
NCT06172127, a Phase 2 study of HER2-positive Breast Cancer, is actively recruiting participants, sponsored by MedSIR.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 165 participants
- Enrollment target
- 20
- Study locations
Study Summary
DEMETHER is a phase II trial exploring the maintenance of trastuzumab and pertuzumab fixed dose combination (FDC) for subcutaneous administration (SC, PHESGO) following trastuzumab deruxtecan (T-DXd) as induction treatment for HER2-positive unresectable locally recurrent or metastatic breast cancer (MBC) patients.
Conditions Studied
Interventions
- DRUG Trastuzumab deruxtecan
- DRUG Phesgo 1,200 MG / 600 MG / 30,000 UNT Per 15 ML Injection
- DRUG Phesgo 600 MG / 600 MG / 20,000 UNT in 10 mL Injection
Study Locations (20)
Other
- Institute Paoli Calmettes - Marseille
- Hopital Europeen Georges Pompidou - Paris
- Hôpital Tenon AP-HP - Paris
- Marienhospital Bottrop GmbH Klinik für Gynäkologie und Geburtshilfe - Bottrop
- Kliniken Essen Mitte - Essen
- Mammazentrum HH - Hamburg
- Klinikum der Universität München - München
- Humanitas Gavazzeni - Bergamo
- Instituto Europeo di Oncologia - Milan
- University Hospital Maggiore della Carita - Novara
- Fondazione Policlinico Universitario Agostino Gemelli - Roma
- Hospital del Vinalopó - Alicante
- Hospital General Universitario Dr. Balmis (Alicante) - Alicante
- Hospital Clínic i Provincial de Barcelona - Barcelona
- Hospital Universitari Dexeus - Barcelona
- Institut Català d' Oncologia L'Hospitalet (ICO) - Barcelona
- Hospital Universitario de Basurto - Bilbao
- Hospital Provincial de Castellón - Castellon
Massachusetts
- Dana-Farber Cancer Institute - Boston
New York
- Northwell Health - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 165 participants |
| Start Date | 2024-07-22 |
| Est. Completion | 2029-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06172127
The ClinicalTrials.gov registry entry for NCT06172127 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 165 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 237-participant average among 54 other HER2-positive Breast Cancer trials with a reported enrollment target (30% lower). The listed sponsor is MedSIR, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with HER2-positive Breast Cancer appearing as the primary indexed condition, and to 3 interventions - of which Trastuzumab deruxtecan is the first listed.
NCT06172127 reports 20 study locations spanning 3 distinct geographic areas - top geographies include Other, Massachusetts, New York.
Frequently Asked Questions
What is clinical trial NCT06172127 about?
NCT06172127 is a clinical study titled "PHESGO Maintenance After T-DXd Short Induction for HER2+ Unresectable Locally Recurrent or Metastatic Breast Cancer". DEMETHER is a phase II trial exploring the maintenance of trastuzumab and pertuzumab fixed dose combination (FDC) for subcutaneous administration (SC, PHESGO) following trastuzumab deruxtecan (T-DXd) as induction treatment for HER2-positive unresectable locally recurrent or metastatic breast cancer ...
What is the current status of trial NCT06172127?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 165 participants. The study started on 2024-07-22. Estimated completion is 2029-05.
What conditions does trial NCT06172127 study?
This clinical trial studies the following conditions: HER2-positive Breast Cancer.
What interventions are being tested in trial NCT06172127?
The interventions under investigation include: Trastuzumab deruxtecan (DRUG), Phesgo 1,200 MG / 600 MG / 30,000 UNT Per 15 ML Injection (DRUG), Phesgo 600 MG / 600 MG / 20,000 UNT in 10 mL Injection (DRUG).
Who is sponsoring clinical trial NCT06172127?
This trial is sponsored by MedSIR, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06172127 being conducted?
This trial has 20 study locations across Massachusetts, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HER2-positive Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer
RECRUITING · Phase 2
-
TRUDI: TDXD+Durva in HER2+/Low IBC
RECRUITING · Phase 2
-
HERizon-Breast: A ctDNA-Guided Adaptive Study of Sequential Anti-HER2 Therapies and CNS Prophylaxis to Induce Long-Term Remission
RECRUITING · Phase 2
-
Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer
RECRUITING · Phase 2
-
A Study of Surgery and Radiotherapy in People With Breast Cancer
RECRUITING · Phase 2
-
Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.